Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors

• DOI: 10.3389/fcvm.2022.1062858
• Publication Date: 2022-12-01T17:54:21Z
• Authors: María Torrente; Mariola Blanco; Fabio Franco; Yago Garitaonaindia; Virginia Calvo; Ana Collazo-Lorduy; Lourdes Gutiérrez; Juan Cristóbal Sá...; Aranzazu González...; Roberto Hernández; Miriam Méndez; Blanca Cantos; Beatriz Núñez; Pedro A. C. Sousa; Mariano Provencio
• Keywords: Immune checkpoint

Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However, despite their excellent therapeutic effect, these medications typically result in a broad spectrum of toxicity reactions. Immune-related cardiotoxicity is uncommon but can be potentially fatal, and its true incidence underestimated clinical trials. The aim this study to assess the identify risk factors for developing cardiac event patients treated with ICIs. We conducted single-institution retrospective study, including ICIs our center. main outcomes were events (CE) cardiovascular death. A total 378 analyzed. CE was 16.7%, during median follow-up 50.5 months. multivariable analysis showed that age, history arrhythmia or ischemic heart disease, prior immune-related adverse significantly associated CE. ICI treatment are more common than currently appreciated. complete initial evaluation recommended, especially high-risk patients, being necessary multidisciplinary approach specialized cardio-oncology team.